Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, describes the potential role of targeting LAG-3 in treating melanoma. LAG-3 will be crucial and developing doublet and triplet therapies and has been identified as a promising target in uveal melanoma, as well as a marker in T cell exhaustion. Dr Hamid additionally highlights advances in the development of CAR-T cells and bispecific antibodies. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.